Cancer immunoprevention (Q28303393)

Europe PubMed Central

title

Cancer immunoprevention (English)

0 references

Patrizia Nanni

6

0 references

Pier-Luigi Lollini

object named as

Pier-Luigi Lollini

1

0 references

Carla De Giovanni

2

object named as

Carla De Giovanni

0 references

Tania Pannellini

3

object named as

Tania Pannellini

0 references

author name string

Federica Cavallo

4

0 references

Guido Forni

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

5

0 references

language of work or name

English

0 references

publication date

February 2005

0 references

published in

Future Oncology

0 references

volume

1

0 references

issue

1

0 references

page(s)

57-66

0 references

cites work

1 reference

https://api.crossref.org/works/10.1517/14796694.1.1.57

Cancer immunoprevention: tracking down persistent tumor antigens

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14796694.1.1.57

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14796694.1.1.57

The immunobiology of cancer immunosurveillance and immunoediting

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Prophylactic cancer vaccines

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

HSP110-HER2/neu Chaperone Complex Vaccine Induces Protective Immunity Against Spontaneous Mammary Tumors in HER-2/neu Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Transgenic mouse models of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Targeted therapy in breast cancer: the HER-2/neu gene and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

DNA vaccination against neu reduces breast cancer incidence and metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

The immunological principles of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Essential roles of Her2/erbB2 in cardiac development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Antitumor vaccines: is it possible to prevent a tumor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.1.57